Drug treatments for schizophrenia

被引：6

作者：

Adams, C

Wilson, P ^{[1
]}

Gilbody, S

Bagnall, AM

Lewis, R

机构：

[1] Univ York, NHS Ctr Reviews & Disseminat, York YO1 5DD, N Yorkshire, England

[2] Cochrane Schizophrenia Grp, Oxford, England

来源：

QUALITY IN HEALTH CARE | 2000年 / 9卷 / 01期

关键词：

D O I：

10.1136/qhc.9.1.73

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

[No abstract available]

引用

页码：73 / 79

页数：7

共 61 条

[51] TAYLOR D, 2000, IN PRESS PRIMARY CAR
[52] Content and quality of 2000 controlled trials in schizophrenia over 50 years
Thornley, B
Adams, C
[J]. BRITISH MEDICAL JOURNAL, 1998, 317 (7167) : 1181 - 1184
[53] THORNLEY B, 1999, COCHRANE LIB
[54] Tollefson GD, 1997, AM J PSYCHIAT, V154, P457
[55] TSUANG MT, 1980, ARCH GEN PSYCHIAT, V37, P979
[56] TUUNAINEN A, 1999, COCHRANE LIB
[57] *UPD SOFTW, 1999, COCHR LIB
[58] *W MACK GLOB CONS, 1998, PHARMAFORUM, V39, P9
[59] What makes an antipsychotic 'atypical'? Conserving the definition
Waddington, JL
OCallaghan, E
[J]. CNS DRUGS, 1997, 7 (05) : 341 - 346
[60] Wahlbeck K, 1999, BRIT MED J, V318, P465